TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
The planned Phase 1 clinical trial includes patients with tumor types with a high frequency of Hippo pathway alterations, including NF2-deficient malignant mesothelioma and some soft tissue sarcomas with YAP/TAZ genetic fusions, including Epithelioid Hemangioendothelioma (EHE), a rare form of soft tissue sarcoma that has a significant unmet medical need with no currently approved therapy […]
Read MoreAs the season of giving and gratefulness is upon us, we want to thank you for being a part of The EHE Foundation family. We appreciate you following our progress and investing in our passion: discovering effective treatments and a cure for EHE. We are thankful for our supporters, partners, and volunteers who make our […]
Read MoreThank you to our wonderful participants, supporters, and sponsors for making our 2021 EHE Fun Run and Walk a tremendous success! Together, more than 900 supporters across the nation helped raise more than $45,000. Thanks to the backing of our sponsors, every penny brought in for this event will go directly to EHE research. This […]
Read MoreFOR IMMEDIATE RELEASEContact: Medha Deoras-Sutliff, [email protected] Hobart, Wisconsin. (October 12, 2021) — The EHE Foundation announced today that it has received a $1 million award from the Margie and Robert E. Petersen Foundation to drive forward progress towards treatments and a cure for Epithelioid Hemangioendothelioma (EHE), a rare vascular cancer. This support provides capacity-building resources […]
Read MoreBiobanking is a brand-new endeavor for us at The EHE Foundation. Researchers retain frozen and stored tissue and biological samples from surgeries, which usually remains within the institution where the procedure takes place. Today, biobanking is a game-changer for rare disease and patient-led organizations like ours. Biobanks accelerate research by safe-guarding high-quality, donated tissue samples […]
Read MoreDr. Rubin used a novel approach to target the gene fusion that causes epithelioid hemgioendothelioma, engineering a novel, first-of-its-kind mouse model of the disease, which will help advance studies to identify new treatments. Click here to read the full article. Sharing exciting news highlighting Dr. Brian Rubin’s research at the Lerner Research Institute at Cleveland […]
Read More